Log in

NASDAQ:AMAGAMAG Pharmaceuticals Stock Price, Forecast & News

$10.57
-0.01 (-0.09 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.33
Now: $10.57
$10.69
50-Day Range
$7.05
MA: $8.87
$10.80
52-Week Range
$4.41
Now: $10.57
$13.53
Volume220,848 shs
Average Volume653,345 shs
Market Capitalization$362.27 million
P/E RatioN/A
Dividend YieldN/A
Beta1.05
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company's products candidates include Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women; AMAG-423, a polyclonal antibody in development for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent for the treatment of oral anticoagulants or low molecular weight heparin. It sells Feraheme to authorized wholesalers and specialty distributors. The company has a license agreement with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio LLC, Perosphere Pharmaceuticals Inc., Antares Pharma, Inc., and Abeona Therapeutics, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Read More
AMAG Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.77 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMAG
CUSIP00163U10
Phone617-498-3300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$327.75 million
Book Value$7.27 per share

Profitability

Net Income$-466,460,000.00

Miscellaneous

Employees467
Market Cap$362.27 million
Next Earnings Date11/6/2020 (Estimated)
OptionableOptionable
$10.57
-0.01 (-0.09 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMAG News and Ratings via Email

Sign-up to receive the latest news and ratings for AMAG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions

How has AMAG Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

AMAG Pharmaceuticals' stock was trading at $6.62 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AMAG shares have increased by 59.7% and is now trading at $10.57.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of AMAG Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AMAG Pharmaceuticals in the last year. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for AMAG Pharmaceuticals
.

When is AMAG Pharmaceuticals' next earnings date?

AMAG Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020.
View our earnings forecast for AMAG Pharmaceuticals
.

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) posted its quarterly earnings data on Thursday, August, 6th. The specialty pharmaceutical company reported ($0.39) EPS for the quarter, topping the Zacks' consensus estimate of ($0.49) by $0.10. The specialty pharmaceutical company had revenue of $52.76 million for the quarter, compared to analysts' expectations of $56.49 million. AMAG Pharmaceuticals had a negative net margin of 88.49% and a negative return on equity of 24.36%.
View AMAG Pharmaceuticals' earnings history
.

What guidance has AMAG Pharmaceuticals issued on next quarter's earnings?

AMAG Pharmaceuticals issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $225-255 million, compared to the consensus revenue estimate of $250.01 million.

What price target have analysts set for AMAG?

7 equities research analysts have issued 12-month price targets for AMAG Pharmaceuticals' stock. Their forecasts range from $6.00 to $14.00. On average, they anticipate AMAG Pharmaceuticals' share price to reach $9.00 in the next twelve months. This suggests that the stock has a possible downside of 14.9%.
View analysts' price targets for AMAG Pharmaceuticals
.

Has AMAG Pharmaceuticals been receiving favorable news coverage?

Press coverage about AMAG stock has been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AMAG Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future.
View the latest news about AMAG Pharmaceuticals
.

Who are some of AMAG Pharmaceuticals' key competitors?

What other stocks do shareholders of AMAG Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AMAG Pharmaceuticals investors own include Palatin Technologies (PTN), Bausch Health Companies (BHC), Celgene (CELG), Gilead Sciences (GILD), Broadcom (AVGO), Energy Transfer LP Unit (ET), Ford Motor (F), Netflix (NFLX), NVIDIA (NVDA) and Skyworks Solutions (SWKS).

Who are AMAG Pharmaceuticals' key executives?

AMAG Pharmaceuticals' management team includes the following people:
  • Dr. William K. Heiden, CEO, Pres & Director (Age 59)
  • Mr. Edward H. Myles, Exec. VP, CFO & Treasurer (Age 47)
  • Mr. Joseph D. Vittiglio, Exec. VP of Legal Affairs and Quality, Gen. Counsel & Corp. Sec. (Age 47)
  • Dr. Julie Krop, Exec. VP of Devel. & Chief Medical Officer (Age 53)
  • Ms. Linda S. Lennox, VP of Investor Relations & Corp. Communications

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

Who are AMAG Pharmaceuticals' major shareholders?

AMAG Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.00%), Bank of America Corp DE (2.43%), Bank of New York Mellon Corp (1.14%), Permanens Capital L.P. (1.05%), Assenagon Asset Management S.A. (1.00%) and Principal Financial Group Inc. (0.77%). Company insiders that own AMAG Pharmaceuticals stock include Armistice Capital Master Fund, Armistice Capital, Llc, Camber Capital Management Lp, Elizabeth Scott Bolgiano, Joseph Vittiglio, Julie Krop and William K Heiden.
View institutional ownership trends for AMAG Pharmaceuticals
.

Which institutional investors are selling AMAG Pharmaceuticals stock?

AMAG stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Permanens Capital L.P., Vanguard Group Inc., Tudor Investment Corp Et Al, Dupont Capital Management Corp, Prudential Financial Inc., Strs Ohio, and State of Tennessee Treasury Department.
View insider buying and selling activity for AMAG Pharmaceuticals
.

Which institutional investors are buying AMAG Pharmaceuticals stock?

AMAG stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Assenagon Asset Management S.A., State of Wisconsin Investment Board, UBS Group AG, ProShare Advisors LLC, Teza Capital Management LLC, Swiss National Bank, and Comerica Bank. Company insiders that have bought AMAG Pharmaceuticals stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc, Camber Capital Management Lp, Elizabeth Scott Bolgiano, Julie Krop, and William K Heiden.
View insider buying and selling activity for AMAG Pharmaceuticals
.

How do I buy shares of AMAG Pharmaceuticals?

Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AMAG Pharmaceuticals' stock price today?

One share of AMAG stock can currently be purchased for approximately $10.57.

How big of a company is AMAG Pharmaceuticals?

AMAG Pharmaceuticals has a market capitalization of $362.27 million and generates $327.75 million in revenue each year. The specialty pharmaceutical company earns $-466,460,000.00 in net income (profit) each year or ($6.88) on an earnings per share basis. AMAG Pharmaceuticals employs 467 workers across the globe.

What is AMAG Pharmaceuticals' official website?

The official website for AMAG Pharmaceuticals is www.amagpharma.com.

How can I contact AMAG Pharmaceuticals?

AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.